NCT04512170View on ClinicalTrials.gov

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

August 23, 2021

Study Completion Date

August 23, 2021

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

HEC585

single or Mulltiple doses up to 10 days

DRUG

placebo

single or Mulltiple doses up to 10 days

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04512170 - Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects | Biotech Hunter | Biotech Hunter